Evidence map›Paper›PMID 12169631›Full record

ArticleThe EMBO journal2002

Keren, a new ligand of the Drosophila epidermal growth factor receptor, undergoes two modes of cleavage.

Aderet Reich, Ben-Zion Shilo

Abstract read
In one paragraph

Article in The EMBO journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Regulatory mechanisms of EGFR signalling during Drosophila eye development.Cellular and molecular life sciences : CMLS · 2016
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aderet ReichDepartment of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.
Ben-Zion Shilo

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spitz (Spi) is the most prominent ligand of the Drosophila EGF receptor (DER). It is produced as an inactive membrane precursor which is retained in the endoplasmic reticulum (ER). To allow cleavage, Star transports Spi to the Golgi, where it undergoes cleavage by Rhomboid (Rho). Since some DER phenotypes are not mimicked by any of its known activating ligands, we identified an additional ligand by database searches, and termed it Keren (Krn). Krn is a functional homolog of Spi since it can rescue the spi mutant phenotype in a Rho- and Star-dependent manner. In contrast to Spi, however, Krn also possesses a Rho/Star-independent ability to undergo low-level cleavage and activate DER, as evident both in cell culture and in flies. The difference in basal activity correlates with the cellular localization of the two ligands. While Spi is retained in the ER, the retention of Krn is only partial. Examining Spi/Krn chimeric and deletion constructs implicates the Spi cytoplasmic domain in inhibiting its basal activity. Low-level activity of Krn calls for tightly regulated expression of the Krn precursor.

Indexed as

Epidermal Growth FactorAmino Acid SequenceAnimalsCell LineDrosophilaDrosophila ProteinsErbB ReceptorsEyeLigandsMembrane ProteinsMolecular Sequence DataProtein Structure, TertiarySequence AlignmentSequence Analysis, DNATransforming Growth Factor alphaWings, AnimalDrosophila ProteinsEpidermal Growth FactorErbB ReceptorsKrn protein, DrosophilaLigandsMembrane ProteinsRho protein, Drosophilaspi protein, DrosophilaS protein, DrosophilaStet protein, DrosophilaTransforming Growth Factor alpha

Identifiers

PMID12169631
PMCPMC126175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.